Drug Profile
Research programme: alpha synuclein positron emission tomography tracers - AC Immune/Biogen
Alternative Names: a-syn-PET imaging agent - AC Immune; Alpha-synuclein-PET based diagnostics - AC ImmuneLatest Information Update: 28 Apr 2023
Price :
$50
*
At a glance
- Originator AC Immune; Biogen
- Class Imaging agents; Radiopharmaceutical diagnostics
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Parkinson's disease
Most Recent Events
- 28 Apr 2023 No recent reports of development identified for preclinical development in Parkinson's-disease(Diagnosis) in Switzerland
- 16 Mar 2023 AC Immune plans a phase I first-in-human study for positron emission tomography (PET) tracer for Parkinson's disease in H2 2023
- 04 Mar 2019 Preclinical trials in Parkinson's disease (Diagnosis) in Switzerland (unspecified route) (AC Immune pipeline, March 2019)